Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070)
South Korea · Delayed Price · Currency is KRW 4,030.00
+135.00 (3.47%)
At close: Oct 2, 2026
Seoulin Bioscience Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 36,397 | 57,463 | 61,462 | 78,767 | 97,546 | 174,747 | |
Market Cap Growth | -34.89% | -6.51% | -21.97% | -19.25% | -44.18% | 62.58% |
Enterprise Value | 21,294 | 37,707 | 39,202 | 46,863 | 48,995 | 136,075 |
Last Close Price | 4030.00 | 6510.00 | 6845.95 | 8533.50 | 10440.22 | 18480.13 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 39.71 | 78.50 | 21.09 | - | 9.60 | 11.21 |
Forward PE | - | 19.70 | 19.70 | 19.70 | 19.70 | 19.70 |
PS Ratio | 0.44 | 0.75 | 0.82 | 0.88 | 0.93 | 2.17 |
PB Ratio | 0.43 | 0.67 | 0.71 | 0.92 | 1.10 | 2.28 |
P/TBV Ratio | 0.44 | 0.69 | 0.74 | 0.96 | 1.17 | 2.36 |
P/FCF Ratio | - | 13.16 | - | - | - | 21.89 |
P/OCF Ratio | 158.67 | 12.07 | - | 84.64 | - | 19.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.26 | 0.49 | 0.52 | 0.52 | 0.47 | 1.69 |
EV/EBITDA Ratio | 12.09 | 20.33 | 16.92 | 12.39 | 4.80 | 14.51 |
EV/EBIT Ratio | 37.25 | 54.52 | 41.15 | 18.79 | 5.33 | 18.26 |
EV/FCF Ratio | - | 8.64 | - | - | - | 17.04 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.16 | 0.14 | 0.04 | 0.08 | 0.20 | 0.21 |
Debt / EBITDA Ratio | 7.84 | 6.24 | 1.59 | 1.78 | 1.74 | 1.68 |
Debt / FCF Ratio | - | 2.65 | - | - | - | 1.97 |
Net Debt / Equity Ratio | -0.20 | -0.27 | -0.23 | -0.34 | -0.42 | -0.78 |
Net Debt / EBITDA Ratio | -10.00 | -12.47 | -8.56 | -7.59 | -3.67 | -6.35 |
Net Debt / FCF Ratio | 171.68 | -5.30 | 4.26 | 1920.12 | 7.78 | -7.46 |
Asset Turnover | 0.73 | 0.70 | 0.70 | 0.72 | 0.77 | 0.75 |
Inventory Turnover | 2.55 | 2.35 | 2.35 | 3.57 | 5.15 | 4.63 |
Quick Ratio | 1.50 | 1.37 | 2.30 | 1.77 | 1.35 | 1.44 |
Current Ratio | 2.73 | 2.28 | 4.39 | 2.60 | 1.88 | 1.77 |
Return on Equity (ROE) | 0.99% | 0.66% | 3.65% | -2.67% | 12.78% | 23.03% |
Return on Assets (ROA) | 0.28% | 0.39% | 0.55% | 1.25% | 4.23% | 4.34% |
Return on Invested Capital (ROIC) | 0.65% | 0.69% | 1.36% | 4.63% | 20.31% | 19.66% |
Return on Capital Employed (ROCE) | 0.60% | 0.80% | 1.10% | 2.90% | 10.30% | 9.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.52% | 1.27% | 4.74% | -0.15% | 10.41% | 8.92% |
FCF Yield | -0.27% | 7.60% | -7.58% | -0.02% | -4.94% | 4.57% |
Payout Ratio | 94.12% | 115.25% | 28.70% | - | 7.86% | 4.93% |
Buyback Yield / Dilution | 57.55% | -10.81% | 2.96% | 19.46% | -23.72% | 0.07% |